Evaluating the Utility of Existing Plasma Biomarkers in a Clinical Patient Cohort

Biomarker assessments will become an instrumental component of effective clinical management and trial coordination for Alzheimer’s Disease (AD) and related dementias and will enable precision medicine approaches to diagnosis and treatment. Plasma offers an inexpensive non‐invasive peripheral biofluid for biomarker assessments that can easily be collected longitudinally. The development of ultrasensitive single molecule array (SIMOA) assays has enabled plasma measurements for AD‐related blood biomarkers. Indeed, several plasma biomarkers were recently identified as potentially useful for AD and related dementias. However, their utility in additional clinical cohorts requires further investigation.